Nuwellis, Inc. NUWE
Nasdaq · XNAS · stock · Electromedical & Electrotherapeutic Apparatus
Chart by TradingView
2/9
Piotroski F — financial health
-177.65
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $8.3M | -$17.5M | $5.1M | -$10.9M | $2.6M |
| 2024 | $8.7M | -$11.2M | $5.7M | -$9.7M | $6.5M |
| 2023 | $8.9M | -$20.2M | $5.0M | -$18.1M | $3.0M |
| 2022 | $8.5M | -$14.5M | $4.8M | -$15.3M | $12.4M |
| 2021 | $7.9M | -$19.6M | $4.5M | -$18.1M | $25.9M |
| 2020 | $7.4M | -$15.8M | $4.1M | -$16.9M | $16.3M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -177.65 (distress)
- Working capital / assets 0.352
- Retained earnings / assets -51.702
- EBIT / assets -1.815
- Equity / liabilities 0.752
Source: SEC EDGAR filings · CIK 0001506492 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.